acute lymphoblastic leukemia
Conditions
Interventions
VCR+Dex group:Low risk patients will be randomized after the reinduction treatment to compare with VCR+Dex and without VCR+Dex
MTX25mg/m2 vs. 40mg/m2:Intermediate and high risk patients will be randomized after the reinduction treatment to compare with MTX 25mg/m2 and MTX 40mg/m2
imatinib vs. dasatinib:Ph+ ALL and sensitive to imatinib and dasatinib Ph-Like-ALL will be randomized to compare efficacy between imatinib and dasatinib
Sponsors
Shanghai Children's Medical Center
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of precursor B-cell or precursor T-cell ALL by immunophenotyping; 2. Younger than 18 years of age; 3. Signing the informed consent.
Exclusion criteria
Exclusion criteria: 1. Mature B-ALL, mixed phenotypic leukemia; 2. secondary neoplasmia; 3. Leukemia secondary to immunodeficiency disease; 4. Participants with prior therapy (emergency radiation to the mediastinum not included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone marrow morphology;Bone marrow minimal residual disease;Bone marrow fusion gene test;Bone marrow Karyotype;FISH translocations;Blood Type;Bone marrow immunophenotype;blood Electrolytes;Blood chemistry;Coagulation;Drug monitoring;Hematology;Microbiology;Pathology;Cerebralspinal Fluid;Urinalysis;Stool studies;HLA Typing;intensive care-Ventilator support;complications;Protocol;Stem Cell Transplant;intensive care-hemodialysis;Surgical cases due to complications; | — |
Countries
China
Contacts
Public ContactShen Shuhong
Shanghai Children's Medical Center
Outcome results
None listed